RNA therapeutics: Identification of novel targets leading to drug discovery

Qadir, Muhammad Imran; Bukhat, Sherien; Rasul, Sumaira; Manzoor, Hamid; Manzoor, Majid

doi:10.1002/jcb.29364

Cited by 42 publications

(17 citation statements)

References 257 publications

(538 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China, ncRNAs have been used for cancer diagnosis in the form of diagnostic kits. Qadir et al (87) attempted to summarize the emerging field of ncRNAs and their role in different diseases, including cancer, their modes of action, and their potential in target identification and therapeutic drug development. In addition, some gene editing techniques have been used for cancer treatment, such as CRISPR.…”

Section: Lncrnas and Mirnas In Cancermentioning

confidence: 99%

Research progress on the interactions between long non‑coding RNAs and microRNAs in human cancer (Review)

Binyu

Liu

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Numerous types of molecular mechanisms mediate the development of cancer. Non-coding RNAs (ncRNAs) are being increasingly recognized to play important role in mediating the development of diseases, including cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are the two most widely studied ncRNAs. Thus far, lncRNAs are known to have biological roles through a variety of mechanisms, including genetic imprinting, chromatin remodeling, cell cycle control, splicing regulation, mRNA decay and translational regulation, and miRNAs regulate gene expression through the degradation of mRNAs and lncRNAs. Although ncRNAs account for a major proportion of the total RNA, the mechanisms underlying the physiological or pathological processes mediated by various types of ncRNAs, and the specific interaction mechanisms between miRNAs and lncRNAs in various physiological and pathological processes, remain largely unknown. Thus, further research in this field is required. In general, the interaction mechanisms between miRNAs and lncRNAs in human cancer have become important research topics, and the study thereof has led to the recent development of related technologies. By providing examples and descriptions, and performing chart analysis, the present study aimed to review the interaction mechanisms and research approaches for these two types of ncRNAs, as well as their roles in the occurrence and development of cancer. These details have far-reaching significance for the utilization of these molecules in the diagnosis and treatment of cancer. Contents 1. Introduction 2. Interactions between lncRNAs and miRNAs 3. Methods of research in to lncRNAs and miRNAs 4. lncRNAs and miRNAs in cancer 5. Conclusion

show abstract

Section: Lncrnas and Mirnas In Cancermentioning

confidence: 99%

Research progress on the interactions between long non‑coding RNAs and microRNAs in human cancer (Review)

Binyu

Liu

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The therapeutic effects are achieved through the regulation of RNA maturation, splicing, interference, translation and stabilisation. More possibilities of drug formats and therapeutic mechanisms have been discussed, including peptides [182], aptamers [183] and RNA editing with CRISPR-Cas13 [184]. Over the past five years, an increasing number of RNA-targeted drugs have been approved.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

RNA-Targeted Therapies and High-Throughput Screening Methods

Zhu

Rooney

Michlewski

2020

IJMS

View full text Add to dashboard Cite

RNA-binding proteins (RBPs) are involved in regulating all aspects of RNA metabolism, including processing, transport, translation, and degradation. Dysregulation of RNA metabolism is linked to a plethora of diseases, such as cancer, neurodegenerative diseases, and neuromuscular disorders. Recent years have seen a dramatic shift in the knowledge base, with RNA increasingly being recognised as an attractive target for precision medicine therapies. In this article, we are going to review current RNA-targeted therapies. Furthermore, we will scrutinise a range of drug discoveries targeting protein-RNA interactions. In particular, we will focus on the interplay between Lin28 and let-7, splicing regulatory proteins and survival motor neuron (SMN) pre-mRNA, as well as HuR, Musashi, proteins and their RNA targets. We will highlight the mechanisms RBPs utilise to modulate RNA metabolism and discuss current high-throughput screening strategies. This review provides evidence that we are entering a new era of RNA-targeted medicine.

show abstract

“…This realization of this concept is possible due to significant developments in genetic engineering. For example, the targeted genetic deletion of Malat1 by zinc finger nucleases 57 and synthetic oligonucleotides designed to Malat1 as a therapeutic target, including siRNAs and locked nucleic acid (LNA) gapmer antisense oligonucleotides (ASOs), [58][59][60] are worthy of consideration.…”

Section: Modulating the Disease Processmentioning

confidence: 99%